Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-01-26
1997-09-16
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3147
Patent
active
056681496
ABSTRACT:
Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including amodiaquin, chloroquine, hydroxychloroquine, primoquine, quinacrine and compounds having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, or join to form a cyclic structure of the formula: ##STR2## and R.sup.3 and R.sup.4, same or different, are hydrogen, C.sub.1 -C.sub.8 lower alkyl or hydroxy substituted C.sub.1 -C.sub.8 lower alkyl, and the pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 5153202 (1992-10-01), Davis
B.S. Stein et al, Cell, vol. 49, pp. 659-668, Jun. 5, 1987.
Stedman's Medical Dictionary, 23rd Edition, pp. 461 and 495.
Kagan, West J. Med, 146 (2), p. 234, Feb., 1987.
Chemical Abstracts 113: 536f (1990) Abstracting PCT Int. Application WO 90 00,055 Jan. 11, 1990.
Kung Hsiang-Fu
Nara Peter L.
Oroszlan Stephen
Tsai Wen-Po
Goldberg Jerome D.
The United States of America as represented by the Department of
LandOfFree
Inhibition of human immunodeficiency virus-1 infectivity in huma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of human immunodeficiency virus-1 infectivity in huma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of human immunodeficiency virus-1 infectivity in huma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218567